Lunit’s Year of 2022: Turning Possibility into Reality
Dec 28, 2022 — 8 min read
Jihye Park
2022 Milestones of Lunit
For Lunitians, 2022 was all about making another giant leap toward growth. In the midst of going back to pre-pandemic normalcy and unexpected tough days that hit most of us, we managed to get through, still strong and hopeful.
2022 was a particularly special year for us, as we made a series of significant achievements that led us a step closer to our goal of conquering cancer through AI. Thus, we themed the year 2022 ‘turning possibility into reality.’
Watch the 2022 recap video below to see the milestones we reached throughout the year.
2022 Milestones of Lunit video
IPO
▪ Lunit made its stock market debut on the Korea Exchange in July. As a global medical AI company, we strive to continue our mission of conquering cancer through AI, bringing state-of-the-art innovations to the medical industry.
▶ Read the Article: AI-based Cancer Solution Pioneer Lunit Makes Market Debut
1,000 Hospitals
▪ Our customer sites have now reached more than 1,000 around the world. In Japan, our AI was deployed in more than 100 sites within 6 months after launching. Major hospitals around the world are showing interest and adopting our software: Bumrungrad in Thailand, Einstein in Brazil, Abu Dhabi Health Services, and more.
First AI in National Breast Screening
▪ Lunit INSIGHT has been selected as an AI for the national breast screen program in New South Wales, Australia. AI application in national breast screening is a first of its kind, and we look forward to seeing more women benefit from more accurate and earlier detection of breast cancer through AI.
▶ Read the Article: Lunit to Supply AI Platform to Australia’s BreastScreen NSW Machine Reading Project
Collaboration with Guardant Health
▪ In partnership with Guardant Health, a global precision oncology company, we introduced a new AI-based PD-L1 test aimed at helping better analyze PD-L1 expression in tissue samples by using AI.
MDR CE and UKCA Certified
▪ Lunit became the first medical software company in Asia-Pacific to become MDR CE and UKCA certified. By obtaining strict certifications, Lunit has been accelerating our business expansion into the European market.
▶ Read the Article: Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified
CE Mark
▪ We received CE Mark for Lunit SCOPE PD-L1, a first for our Lunit SCOPE product line. With the certification, we officially launched Lunit SCOPE and entered the European market.
A Prospective Study
▪ The clinical efficacy of Lunit’s AI has been validated by the first prospective research on AI used in actual clinical settings. The study demonstrated that Lunit INSIGHT could be used in real-world breast screening settings effectively.
▶ Read the Article: Lunit Unveils Real-World Data Backing Clinical Efficacy of AI for the First Time in Breast Cancer Research; Abstracts to be Presented at RSNA 2022
Major Publications
▪ A series of clinical trials on Lunit SCOPE as a novel biomarker to predict immunotherapy response were published in prestigious peer-reviewed journals(J Clin Oncol, Clin Cancer Res, Cancer Res, Eur J Cancer) and presented at international conferences(USCAP, ASCO, AACR, ESMO, SITC).
▶ Visit Lunit’s website and read our papers!
Lunit CARE
▪ Lunit CARE was launched in Korea to support cancer patients and their families through one-on-one consultations and information.
Community
▪We have been restless in our journey to create a larger community that supports Lunit in our mission to conquer cancer through AI. This year, we saw dramatic growth in our LinkedIn followership growing 181%. Along with it, our Instagram followers and YouTube viewers also showed great interest.
Didn’t follow yet? Follow right now!
➊Follow Lunit Linkedin